Thursday - November 21, 2024
GSK: Blenrep Shows Overall Survival Benefit in Head-to-Head DREAMM-7 Phase III Trial for Relapsed/Refractory Multiple Myeloma
November 15, 2024
LONDON, England, Nov. 15 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Nov. 14, 2024:

* * *

- Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex

- Full data to be presented at 2024 American Society of Hematology Annual Meeting in December

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products